Drugs / hCART19s
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02782351 | May 2016 → Jun 2018 | B-cell chronic lymphocytic leukemia | Kai Lin Xu; Jun Nian Zheng | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hCART19s | “In this retrospective study of humanized CD19-targeted CAR-T cell (hCART19s) therapy for R/R B-ALL, we analyzed the patients treated with allogeneic hematopoietic stem cell...” PMID 34777367 ↗ Oct 2021 |
| Known as | CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02782351 ↗ |
| Modality | Cell therapy | “humanized Chimeric antigen receptor T cells (CAR-T)” NCT02782351 ↗ |
| Target | CD19 | “By targeting the CD19 antigen” PMID 24311149 ↗ Dec 2013 |